Yervoy

Indication

• For the treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older.
• For the treatment of adult patients with unresectable or metastatic melanoma, in combination with nivolumab.
• For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
• For the treatment of patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab.
• For the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab.
• For the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, in combination with nivolumab.
• For the treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab.
• For the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.
• For the treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab.

More on this drug: Clinical Trials